Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G, Bartels L, Kedde M, Verdegaal EME, Gillissen MA, Levie SE, Cercel MG, van Hal-van Veen SE, Fatmawati C, van de Berg D, Yasuda E, Claassen YB, Bakker AQ, van der Burg SH, Schotte R, Villaudy J, Spits H, Hazenberg MD, van Helden PM, Wagner K. de Jong G, et al. Among authors: van helden pm. Cancer Immunol Immunother. 2021 Jun;70(6):1569-1581. doi: 10.1007/s00262-020-02780-9. Epub 2020 Nov 23. Cancer Immunol Immunother. 2021. PMID: 33225419 Free PMC article.
A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L, de Jong G, Gillissen MA, Yasuda E, Kattler V, Bru C, Fatmawati C, van Hal-van Veen SE, Cercel MG, Moiset G, Bakker AQ, van Helden PM, Villaudy J, Hazenberg MD, Spits H, Wagner K. Bartels L, et al. Among authors: van helden pm. Cancer Res. 2019 Jul 1;79(13):3372-3382. doi: 10.1158/0008-5472.CAN-18-0189. Epub 2019 May 7. Cancer Res. 2019. PMID: 31064847
AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses.
Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD. Gillissen MA, et al. Among authors: van helden pm. Bone Marrow Transplant. 2016 Sep;51(9):1245-8. doi: 10.1038/bmt.2016.90. Epub 2016 Apr 18. Bone Marrow Transplant. 2016. PMID: 27088384 No abstract available.
AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses.
Gillissen MA, Kedde M, Jong G, Moiset G, Yasuda E, Levie SE, Bakker AQ, Claassen YB, Wagner K, Böhne M, Hensbergen PJ, Speijer D, van Helden PM, Beaumont T, Spits H, Hazenberg MD. Gillissen MA, et al. Among authors: van helden pm. Blood. 2018 Jan 4;131(1):131-143. doi: 10.1182/blood-2017-02-768762. Epub 2017 Oct 23. Blood. 2018. PMID: 29061569 Free article.
Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice.
Gillissen MA, de Jong G, Kedde M, Yasuda E, Levie SE, Moiset G, Hensbergen PJ, Bakker AQ, Wagner K, Villaudy J, van Helden PM, Spits H, Hazenberg MD. Gillissen MA, et al. Among authors: van helden pm. Blood Adv. 2017 Aug 18;1(19):1551-1564. doi: 10.1182/bloodadvances.2017008342. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296797 Free PMC article.
CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.
Steinitz KN, van Helden PM, Binder B, Wraith DC, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Weiller M, Lubich C, de la Rosa M, Schwarz HP, Reipert BM. Steinitz KN, et al. Among authors: van helden pm. Blood. 2012 Apr 26;119(17):4073-82. doi: 10.1182/blood-2011-08-374645. Epub 2012 Mar 6. Blood. 2012. PMID: 22394599 Free PMC article.
20 results